Related Experiment Video
Updated: Feb 9, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation
Frederick H Wilson1,2,3, Katerina Politi1,3,4
1Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu frederick.wilson@yale.edu.
Abstract:
A patient with advanced lung adenocarcinoma harboring a CD74-NRG1 gene rearrangement, which promotes ERBB2-ERBB3 heterodimerization and activation of downstream signaling, had an exceptional therapeutic response to an experimental anti-ERBB3 antibody. This result illustrates how NRG1 rearrangements, which are observed at a low frequency in a variety of solid tumors, may represent tractable therapeutic targets. Cancer Discov; 8(6); 676-8. ©2018 AACR.See related article by Drilon et al., p. 686.
Insights
A patient with a specific gene rearrangement (CD74-NRG1) in lung cancer responded exceptionally well to an experimental ERBB3 antibody. This finding highlights NRG1 rearrangements as potential targets for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung adenocarcinoma can harbor specific gene rearrangements.
- CD74-NRG1 rearrangements activate ERBB2-ERBB3 signaling pathways.
- NRG1 rearrangements are found in various solid tumors at low frequencies.
Purpose of the Study:
- To investigate the therapeutic potential of targeting ERBB3 in patients with CD74-NRG1 rearrangements.
- To assess the clinical response to an anti-ERBB3 antibody in a patient with advanced lung adenocarcinoma and this specific gene rearrangement.
Main Methods:
- Case study of a patient with advanced lung adenocarcinoma.
- Analysis of tumor genomics for gene rearrangements.
- Administration of an experimental anti-ERBB3 antibody therapy.
- Evaluation of therapeutic response.
Main Results:
- The patient exhibited an exceptional therapeutic response to the anti-ERBB3 antibody.
- The CD74-NRG1 rearrangement was identified as the underlying molecular driver.
- This specific rearrangement promotes ERBB2-ERBB3 heterodimerization and downstream signaling activation.
Conclusions:
- Targeting ERBB3 is a viable therapeutic strategy for cancers with CD74-NRG1 rearrangements.
- NRG1 rearrangements represent actionable targets across various solid tumors.
- Personalized medicine approaches can yield significant clinical benefits for patients with rare genetic alterations.
More Related Videos
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
What is Cell Signaling?
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway

